SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 CLINICAL TRIAL FOR MR-301 IN SEVERE TBI PRINCETON ...
MR-101 is a novel formulation candidate in SHINKEI’s CNS pipeline being developed for movement disorders. Like other SHINKEI product candidates, MR-101 is being advanced using the 505 (b) (2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results